Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098806 | 1.00 | USP2 (0.50) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL668469 | 1.00 | USP2 (0.50) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL29351668 | 1.00 | USP2 (0.50) | USP2PKMALOX15HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL29175072 | 0.98 | USP2 (0.49) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL15345630 | 0.86 | USP2 (0.50) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL5288482 | 0.86 | USP2 (0.50) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL2028058 | 0.85 | KDM4E (0.62) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL2028640 | 0.85 | KDM4E (0.62) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL2177581 | 0.85 | KDM4E (0.55) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL38096 | 0.85 | KDM4E (0.55) | USP2PKMALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001922-A1 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | UNIV CALIFORNIA (US) | 2026-01-01 | — | — | US | claimed |
| WO-2024011119-A2 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-11 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260001922-A1 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | UNIV CALIFORNIA (US) | 2026-01-01 | — | — | US | disclosed |
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | PALATIN TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| EP-0848718-A1 | CYTOLYTIC BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1997009347-A1 | CYTOLYTIC BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997009346-A1 | DES-ARG9-BK ANTAGONISTS | CORTECH, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1996016081-A1 | BRADYKININ ANTAGONIST PEPTIDES CONTAINING INDANE-SUBSTITUTED AMINO ACIDS | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | USP2 1191/4885PKM 3315/4885ALOX15 1035/4885 |
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | MC4R, MC1R, MC3R | USP2 4805/4885PKM 2768/4885ALOX15 3157/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | USP2 1191/4885PKM 3315/4885ALOX15 1035/4885 |
| US-20260001922-A1 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | TPX2, XBP1, SCN9A | USP2 3598/4885PKM 3978/4885ALOX15 3239/4885 |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | MC1R, MC3R, MC5R | USP2 3404/4885PKM 3629/4885ALOX15 1449/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | USP2 1191/4885PKM 3315/4885ALOX15 1035/4885 |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | USP2 874/4885PKM 3543/4885ALOX15 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.